In many solid tumors, PD-1 is upregulated in the tumor-infiltrating lymphocytes (TILs), whereas its ligands PD-L1 and PD-L2 (less commonly) are expressed by a variety of tumor cells, contributing to the impairment in antitumor immunity [8]. This evidence concerns the gene CD274 and neoplasm.